Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Loncastuximab tesirine (Primary) ; Melphalan (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 11 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.
  • 04 Jan 2023 Planned initiation date changed from 7 Dec 2022 to 1 Apr 2023.
  • 07 Nov 2022 Planned initiation date changed from 3 Nov 2022 to 7 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top